10 Biggest Stocks with Negative Beta to Consider

2. Structure Therapeutics (NASDAQ:GPCR)  

Number of Hedge Fund Investors: 43  

Beta: -3.52  

Market Cap as of October 13: $2.19 Billion  

Structure Therapeutics (NASDAQ:GPCR) is a biotechnology company developing oral therapies targeting G-protein-coupled receptors (GPCRs) for various diseases. GPCRs are a group of proteins in the cell membrane that receive signals and convert them into physiological effects.

Structure Therapeutics (NASDAQ:GPCR) is also developing innovative treatments for various diseases, including obesity and type 2 diabetes. The company’s lead candidate, GSBR-1290, is an oral GLP-1 agonist that has shown promising weight loss results and a strong safety profile in early clinical trials.

Glucagon-like peptide-1 (GLP-1) agonist drugs have taken the pharmaceutical world by storm due to their ability to suppress appetite and help patients lose weight with minimal side effects. The market for GLP-1 agonists is expected to be worth over $100 billion by 2030, making it one of the most lucrative markets in the pharmaceutical industry. The company’s GSBR-1290 is an oral small-molecule product that targets the GLP-1 receptor. The drug has shown statistically significant weight loss results in early clinical trials and has a strong safety profile, with no serious adverse events reported. Structure Therapeutics (NASDAQ:GPCR) plans to initiate a Phase 2b obesity study in the fourth quarter of this year.

The GLP-1 agonist market is highly competitive, with several pharmaceutical companies, developing their own candidates. However, Structure Therapeutics’ oral GLP-1 candidate has a unique advantage over injectable therapies, making it a potentially strong player in the market.

Structure Therapeutics’ (NASDAQ:GPCR) progress and diverse pipeline of candidates make it a potentially strong investment opportunity. Industry analysts are extremely bullish on the company’s stock price and have a consensus Buy rating at a target price of $87.90, which implies a 78.56% increase from its current level.